A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 6, 2010, Pages 727-734

  Hamberg, A K ^a   Wadelius, M ^a   Lindh, J D ^b   Dahl, M L ^b   Padrini, R ^c   Deloukas, P ^d   Rane, A ^b   Jonsson, E N ^e,f  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF PADOVA   (Italy)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^e UPPSALA UNIVERSITY   (Sweden)

^f Exprimo NV   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; RETROSPECTIVE STUDIES; TIME FACTORS; WARFARIN; YOUNG ADULT;

EID: 77952581568     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.37     Document Type: Article

References (30)

1. Millican, E.A. et al. Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood 110, 1511-1515 (2007).
2. Sconce, E.A. et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106, 2329-2333 (2005).
3. Gage, B.F. et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84, 326-331 (2008).
4. Wadelius, M. et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113, 784-792 (2009)
5. International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360, 753-764 (2009).
6. Schwarz, U.I. et al. Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J. Med. 358, 999-1008 (2008).
7. Caraco, Y., Blotnick, S. & Muszkat, M. CYP2C9 genotype-guided warfarin prescribing enhances the efcacy and safety of anticoagulation: a prospective randomized controlled study. Clin. Pharmacol. Ther. 83, 460-470 (2008)
8. Lindh, j.D., Lundgren, S., Holm, L., Alfredsson, L. & Rane, A. Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clin. Pharmacol. Ther. 78, 540-550 (2005)
9. Lindh, j.D., Holm, L., Dahl, M.L., Alfredsson, L. & Rane, A. Incidence and predictors of severe bleeding during warfarin treatment. J. Thromb. Thrombolysis 25, 151-159 (2008).
10. Higashi, M.K. et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287, 1690-1698 (2002).
11. Limdi, N.A. et al. Infuence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin. Pharmacol. Ther. 83, 312-321 (2008).
12. Anderson, J.L. et al.; Couma-Gen Investigators. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116, 2563-2570 (2007).
13. Kim, M.J., Huang, S.M., Meyer, U.A., Rahman, A. & Lesko, L.j. A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity. J. Clin. Pharmacol. 49, 138-146 (2009).
14. Lesko, L.J. The critical path of warfarin dosing: fnding an optimal dosing strategy using pharmacogenetics. Clin. Pharmacol. Ther. 84, 301-303 (2008).
15. Silber, H.E., jauslin, P.M., Frey, N., Gieschke, R., Simonsson, U.S. & Karlsson, M.O. An integrated model for glucose and insulin regulation in healthy volunteers and type 2 diabetic patients following intravenous glucose provocations. J. Clin. Pharmacol. 47, 1159-1171 (2007).
16. Friberg, L.E., Henningsson, A., Maas, H., Nguyen, L. & Karlsson, M.O. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J. Clin. Oncol. 20, 4713-4721 (2002).
17. Jonsson, E.N., Macintyre, F., James, I., Krams, M. & Marshall, S. Bridging the pharmacokinetics and pharmacodynamics of UK-279,276 across healthy volunteers and stroke patients using a mechanistically based model for target-mediated disposition. Pharm. Res. 22, 1236-1246 (2005).
18. Jönsson, S. & Karlsson, M.O. A rational approach for selection of optimal covariate-based dosing strategies. Clin. Pharmacol. Ther. 73, 7-19 (2003).
19. Hamberg, A.K. et al. A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. Clin. Pharmacol. Ther. 81, 529-538 (2007).
20. Lindh, J.D., Holm, L., Andersson, M.L. & Rane, A. Infuence of CYP2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis. Eur. J. Clin. Pharmacol. 65, 365-375 (2009).
21. Yang, L., Ge, W., Yu, F. & Zhu, H. Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement\a systematic review and meta analysis. Thromb. Res.125, e159-e166 (2010).
22. van Schie, R.M. et al. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 10, 1687-1695 (2009).
23. Rowland, M. & Tozer, T.N. Clinical Pharmacokinetics: Concepts and Applications. 3rd edn. (Williams & Wilkins, Baltimore, MD, 1995).
24. Levy, G. Kinetics of pharmacologic activity of succinylcholine in man. J. Pharm. Sci. 56, 1687-1688 (1967).
25. Gabrielsson, J., jusko, W.J. & Alari, L. Modeling of dose-response-time data: four examples of estimating the turnover parameters and generating kinetic functions from response profles. Biopharm. Drug Dispos. 21, 41-52 (2000).
26. Jacqmin, P. et al. Modelling response time profles in the absence of drug concentrations: defnition and performance evaluation of the K-PD model. J. Pharmacokinet. Pharmacodyn. 34, 57-85 (2007).
27. Bertola, J.P., Mazoyer, E., Bergmann, J.F., Drouet, L., Simoneau, G. & Mahé, I. Early prediction of the sensitivity of warfarin in elderly patients by the fall in factor VIIc and protein C at the induction of treatment. Thromb. Res. 109, 287-291 (2003).
28. D'Angelo, A., Della Valle, P., Crippa, L., Fattorini, A., Pattarini, E. & Viganò D'Angelo, S. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment. Haematologica 87, 1074-1080 (2002).
29. Beal, S.L. & Sheiner, L.B. NONMEM Users Guides (Icon Development Solutions, Ellicott City, MD, 1989)
30. jonsson, E.N. & Karlsson, M.O. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58, 51-64 (1999).